Shield Therapeutics - Feraccru®/Accrufer® publications
("Shield" or the "Group" or the "Company")
The study concluded that ferric maltol was well tolerated by the majority of patients and resulted in significant improvements in iron status and haemoglobin levels after 12 weeks of treatment. These changes were accompanied by signs of improved right ventricular function and improved exercise capacity, supporting the notion that iron deficiency has detrimental effects in patients with PH and that treating iron deficiency anaemia in these patients is important. Despite the limitations of a small open label study, the results suggest that oral iron supplementation with ferric maltol might become a safe, effective and convenient treatment option for patients with PH and iron deficiency.
Shield provided the study medication for this study but did not provide financial or logistic support and was not involved in data analysis or writing of this manuscript.
The paper is available online here: https://erj.ersjournals.com/content/erj/early/2020/05/19/13993003.00616-2020.full.pdf
The paper is available online here: https://www.mdpi.com/2077-0383/9/5/1536
For further information please contact:
| || |
+44 (0)20 7186 8500
| || |
Nominated Adviser and Joint Broker
| || |
| || |
+44 (0)20 7418 8900
+44 (0)20 7220 0500
Financial PR & IR Advisor
+44 (0)20 7933 8780 or [email protected]
Paul McManus/Lianne Cawthorne
+44 (0)7980 541 893 / +44 (0)7584 391 303
Shield is a de-risked, commercial stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives. The Group's lead product, Feraccru®/ Accrufer® has exclusive IP rights until the mid-2030s and is approved for the treatment of iron deficiency with or without anaemia in adults in the
Feraccru®/Accrufer® is a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia that has been shown to be an efficacious and well-tolerated therapy in a range of controlled phase 3 trials, and offers a compelling alternative to IV iron for those patients unable to tolerate salt-based oral iron therapies and wish to avoid the complexities of infusion-based iron therapies.
When salt-based oral iron therapies are ingested they can cause a range of mild-to-severe gastrointestinal tract (GI) adverse events, including nausea, bloating and constipation through the release and subsequent reactivity of free iron in the GI tract, leading to poor tolerability, reduced patient compliance and ultimately treatment failure. Feraccru®/Accrufer® is not an iron salt and, as a result, it does not routinely cause the same treatment-limiting intolerance issues of salt-based iron therapies, whilst the iron from the ferric maltol molecule can be readily absorbed.
Prior to Feraccru®/Accrufer®, IV iron therapies were the only realistic alternative treatment option for iron deficient patients with or without anaemia intolerant of or unwilling to be treated salt-based oral iron therapies. However, use of such an invasive, costly, inconvenient and complex to administer treatment option, which is associated with potentially life-threatening and spontaneous hypersensitivity reactions, means there remains a clear unmet medical need for these patients to have access to an effective therapy that is well tolerated, convenient and does not require hospital-based administration. Feraccru®/Accrufer® meets those requirements.
About Iron Deficiency
The WHO states that iron deficiency is the most common and widespread nutritional disorder in the world. As well as affecting a large number of women and children in non-industrialized countries, it is the only nutrient deficiency which is also significantly prevalent in virtually all industrialised nations. There are no current global figures for iron deficiency but, using anaemia as an indirect indicator, it can be estimated that most preschool children and pregnant women in non-industrialised countries, together with at least 30-40% in industrialized countries, are iron deficient.
This information is provided by RNS, the news service of the
Quick facts: Shield Therapeutics PLC
Market Cap: £154.1 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE